SavedAdd your journal

Journals / Namık Kemal Tıp Dergisi / 2013 / Cilt: 1 Sayı: 1

-

Asimetrik Dimetil Arjinin (ADMA) Metabolizması

Murat AYDIN
Ferah ARMUTÇU
Muhammet YİĞİTOĞLU
Pages
61–66
Publication Date
2015-03-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review we will study ADMA structure, synthesis, metabolism and its relationship with clinical conditions

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Asymmetric dimethyl arginine (ADMA) is an endogenous inhibitor of Nitric Oxide Synthase (NOS) enzyme.
📊
Key Findings & Data:Methylated arginine has been found in human urine for the first time in the 1970s.
💡
Conclusion & Impact:In this review we will study ADMA structure, synthesis, metabolism and its relationship with clinical conditions
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Asimetrik dimetil arjinin · nitrik oksit · ADMA

Abstract

Asymmetric dimethyl arginine (ADMA) is an endogenous inhibitor of Nitric Oxide Synthase (NOS) enzyme. Methylated arginine has been found in human urine for the first time in the 1970s. However the first study with ADMA has been made among patients with chronic renal failure in 1992. It has been reported by many studies that ADMA contributed in endothelial dysfunction and atherosclerosis and can be used as a marker in recent years. ADMA was found to be elevated in the serum in cases of renal insufficiency, atherosclerosis, hyperglycemia and in hyperhomocysteinemia. In this review we will study ADMA structure, synthesis, metabolism and its relationship with clinical conditions

Özet

Asimetrik dimetil arjinin (ADMA) endojen Nitrik Oksit Sentaz enzimi (NOS) inhibitörüdür. İlk kez 1970 yıllarında metillenmiş arjininler insan idrarında saptanmıştır. Ancak ADMA ile ilgili ilk çalışma 1992’de Vallance ve arkadaşları tarafından kronik böbrek yetmezliği hastalarında yapılmıştır. Son yıllarda yapılan çok sayıda çalışmada ADMA’nın endotel disfonksiyonu ve atherosklerozda rol aldığı ve belirteç olarak kullanılabileceği bildirilmiştir. ADMA’nın ayrıca, böbrek yetmezliği, ateroskleroz, hiperglisemi, hiperhomosisteinemi durumlarında da serumda yükseldiği tespit edilmiştir. Biz bu derlemede ADMA’nın yapısı, sentezi, metabolizması ve klinik durumlar ile ilşkisini inceleyeceğiz.

🔖

Cite This Article

AYDIN, M., ARMUTÇU, F., YİĞİTOĞLU, M. (2015). -. Namık Kemal Tıp Dergisi, Cilt: 1 Sayı: 1, 61–66. https://ajindex.com/articles/975350

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Cekmen MB, Turgut M, Turkoz Y, et al. Nitric Oxide and Nitric Oxide Synthaze Physiologic and Pathologic Characterictics. T Klin J Ped. 2001;10(4):226-35.
  2. Moncada S, Palmer RMJ, Higgs EA. Biosynthesis of nitric oxide from L-arginin: A pathway for the regülation of cell function and communication. Biochem Pharmacol 1989;38(11):1709-15.
  3. Raghavan SA, Dikshit M. Vascular regulation by the L- arginine metabolites, nitric oxide and agmatine. Pharmacol Res. 2004;49(5):397-414. Anggard E. Nitric Oxide: Mediator, murderer and medicine. The Lancet 1994; 343(8907):1199-206
  4. Gritti P, Lanterna LA, Re M, et al. The use of inhaled nitric oxide and prone position in an ARDS patient with severe traumatic brain injury during spine stabilization. J Anesth 2012; DOI: 10.1007/s00540-012-1495-2 [Epub ahead of print]. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb. Vasc Biol 2000;20(9):2032-7.
  5. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339(8793):572-5. 8. Valkonen V-P, Laaksonen R. Asymmetric dimethylarginine (ADMA) and acute vascular events. Clin Chim Acta: 2004;348(1-2):9-17.
  6. Tarnow L, Hovind P, Teerlink T, et al. Elevated plasma ADMA as a marker of cardiovascular morbidity in early diabetic nephropathy in Type 1 diabetes. Diabetes Care 2004;27(3):765-9.
  7. Hu T, Chouinard M, Cox Amy L, et al. X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J Biol Chem, 2006;281(52):39831-8.
  8. Mittermayer F, Pleiner J, Krzyzanowska K, et al. Regular physical exercise normalizes elevated ADMA concentrations in patients with Type 1 Diabetes mellitus. Wien Klin Wochenschr. 2005;117(23-24):816- 20. Beltowski J, Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep. 2006;58(2):159-78.
  9. Nijveldt RJ, Siroen MPC, Teerlink T, Leeuwen MV. Elimination of Asymmetric Dimethylarginine by the Kidney and the Liver: A Link to the development of multiple organ failure. J. Nutr. 2004;134 (Supl. 10):2848S-52S. Böger RH, Maas R, Schulze F, Schwedhelm E. Elevated levels of ADMA as a marker of cardiovascular disease and mortality. Clin Chem Lab Med. 2005;43(10):1124-9
  10. Wang J, Sim AS, Wang XL, et al. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis. 2006;184(2):383-8.
  11. Valkonen VP, Tuomainen TP, Laaksonen R.